文献速递咽喉与嗓音

声带麻痹中Trafermin最佳剂量及注射前因素研究

Investigation of Optimal Trafermin Dosage and Pre-Injection Factors in Vocal Fold Paralysis.
PubMed 文献 · Laryngoscope · 2025-10-23

本研究回顾性分析2012至2024年东京嗓音中心198例单侧声带麻痹接受声带内Trafermin注射的患者,按剂量分为低剂量(<100μg,12例)、常规剂量(100μg,152例)和高剂量(>100μg,34例)。结果显示高剂量组在最大发声时间、平均气流率和嗓音障碍指数方面改善显著优于常规剂量组,注射前指标和合并症是重要预测因素。

要点

  • 高剂量Trafermin(>100μg)可能带来更显著且持久的嗓音改善。
  • 注射前MPT、MFR、VHI及合并症可预测疗效,助力个体化治疗。
  • 常规剂量100μg组仍占多数,但高剂量组在多项指标上更优。

核心结论

  • 较高剂量Trafermin可能为单侧声带麻痹患者提供更大且更持久的嗓音改善。
  • 基于注射前因素筛选合适候选者有助于实现更个性化治疗。

研究设计与样本

  • 回顾性研究,纳入2012至2024年东京嗓音中心198例接受声带内Trafermin注射的单侧声带麻痹患者。
  • 按剂量分组:低剂量<100μg(12例)、常规剂量100μg(152例)、高剂量>100μg(34例)。

主要发现

  • 注射后各组最大发声时间改善分别为:常规组3.03秒、低剂量组3.13秒、高剂量组5.57秒。
  • 音域改善分别为:常规组6.82半音、低剂量组4.5半音、高剂量组8.74半音。
  • 平均气流率改善分别为:常规组191.28 mL/s、低剂量组121.02 mL/s、高剂量组409.63 mL/s(8例缺失)。
  • 嗓音障碍指数改善分别为:常规组21.75分、低剂量组1.83分、高剂量组33.45分(3例缺失)。
  • 方差分析显示组间MPT、MFR和VHI改善显著;Dunnett检验显示高剂量组显著优于常规组;协方差分析确定注射前值和合并症为显著预测因素。

临床怎么用

  • 临床可考虑对单侧声带麻痹患者使用较高剂量Trafermin以增强嗓音改善效果。
  • 注射前应评估MPT、MFR、VHI及合并症,以个体化选择治疗候选者。

局限性

  • 回顾性研究设计,可能存在选择偏倚和信息偏倚。
  • 低剂量组样本量较小(12例),可能影响统计效能。
  • 部分数据缺失(MFR缺失8例,VHI缺失3例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Optimal trafermin dosages and outcome predictors for treating unilateral vocal fold paralysis (UVFP) remain unclear. We aimed to investigate the optimal trafermin dosage and pre-injection factors contributing to voice improvement after intracordal trafermin injection (ITI) for UVFP. METHODS: Medical records of 198 patients diagnosed with UVFP who received ITI at the Tokyo Voice Center between 2012 and 2024 were retrospectively evaluated. To investigate the effect of ITI on voice improvement prior to trafermin injection, we assessed age, sex, causative diseases, and pre- and post-injection maximum phonation time (MPT), pitch range (PR), mean flow rate (MFR), and voice handicap index (VHI). Patients were categorized by dosage: low (< 100 μg), normal (100 μg), and high (> 100 μg). The normal, low, and high groups comprised 152, 12, and 34 cases, respectively. RESULTS: Following ITI, improvements in the normal, low, and high dosage groups were as follows: MPT (s) (3.03, 3.13, 5.57), PR (ST) (6.82, 4.5, 8.74), MFR (mL/s) (191.28, 121.02, 409.63), and VHI (score) (21.75, 1.83, 33.45) (with data missing for MFR and VHI in eight and three cases, respectively). Analysis of variance revealed significant improvements in MPT, MFR, and VHI among groups. Dunnett's test showed significantly better outcomes in the high-dosage group compared to normal. Covariance analysis identified pre-injection values and comorbidities as significant predictors. CONCLUSION: Higher trafermin dosage may provide greater and more sustained voice improvement in patients with UVFP. Identifying optimal candidates based on pre-injection factors can allow for more personalized treatments.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Hasegawa T, Watanabe Y. Investigation of Optimal Trafermin Dosage and Pre-Injection Factors in Vocal Fold Paralysis. Laryngoscope. 2025. PMID: 41128178. doi:10.1002/lary.70220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。